Roger Hawley

Roger Hawley discloses dealings in 5 companies, chiefly Intermune Inc, Zogenix, Inc. and Cerulean Pharma Inc. In total, 134 filings cover trades dated from 8 February 2006 to 11 April 2019.

Both buying and selling appear: 12 purchases worth €1.3M, against 57 sales worth €14.3M. Taken together, the sales exceed the purchases by €13.0M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 7 share grants and 56 option exercises. So far in 2019, the count stands at 1 purchase and 6 sales.

Half of the purchases are above €77k and half below.

The record was last updated on 15 April 2019 with an open-market purchase (€444k) in Cerulean Pharma Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.